{"organizations": [], "uuid": "4ec89d5f2b25975e4de9241b0c05144055937055", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180201.html", "section_title": "Archive News &amp; Video for Thursday, 01 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-puma-biotechnology-and-canbridge-l/brief-puma-biotechnology-and-canbridge-life-sciences-enter-into-exclusive-licensing-agreement-idUSFWN1PR19S", "country": "US", "domain_rank": 408, "title": "BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-02T05:36:00.000+02:00", "replies_count": 0, "uuid": "4ec89d5f2b25975e4de9241b0c05144055937055"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-puma-biotechnology-and-canbridge-l/brief-puma-biotechnology-and-canbridge-life-sciences-enter-into-exclusive-licensing-agreement-idUSFWN1PR19S", "ord_in_thread": 0, "title": "BRIEF-Puma Biotechnology And Canbridge Life Sciences Enter Into Exclusive Licensing Agreement", "locations": [], "entities": {"persons": [{"name": "canbridge", "sentiment": "none"}], "locations": [{"name": "taiwan", "sentiment": "none"}, {"name": "china", "sentiment": "none"}, {"name": "macau", "sentiment": "none"}, {"name": "hong kong", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "puma biotechnology inc", "sentiment": "negative"}, {"name": "puma", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "puma biotechnology", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 1 (Reuters) - Puma Biotechnology Inc:\n* PUMA BIOTECHNOLOGY AND CANBRIDGE LIFE SCIENCES ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNXÂ® (NERATINIB) IN GREATER CHINA\n* PUMA BIOTECHNOLOGY - CANBRIDGE WILL DEVELOP AND COMMERCIALIZE NERLYNX (NERATINIB) IN MAINLAND CHINA, TAIWAN, HONG KONG, AND MACAU\n* PUMA BIOTECHNOLOGY SAYS WILL RECEIVE UPFRONT PAYMENT OF $30 MILLION\n* PUMA BIOTECHNOLOGY - CO TO GET UPFRONT PAYMENT OF $30 MILLION AND POTENTIAL MILESTONE PAYMENTS TOTALING UP TO $40 MILLION\n* PUMA BIOTECHNOLOGY - TO GET SIGNIFICANT DOUBLE-DIGIT ROYALTIES ON NERLYNX SALES IN GREATER CHINA AND POTENTIAL MILESTONE PAYMENTS Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-02T05:36:00.000+02:00", "crawled": "2018-02-02T13:10:25.001+02:00", "highlightTitle": ""}